OH-GE-AEROSPACE
GE AEROSPACE (GENERAL ELECTRIC COMPANY; NYSE: GE) announced today that, as part of a simplification project following the launch of GE Aerospace as an independent public company, it has submitted applications for the delisting of GE common stock (ISIN Code US3696043013) from Euronext Paris, the London Stock Exchange and the SIX Swiss Exchange (the “Delisting”). This action follows a comprehensive review of the trading volume, cost and administrative requirements related to these listings. Following the Delisting, GE Aerospace shares will continue to be traded on the New York Stock Exchange (“NYSE”), GE Aerospace’s primary listing exchange.
The following required information is provided in connection with the Delisting from Euronext Paris. The Delisting has been approved by the Listing Board of Euronext Paris S.A.
Information Regarding Delisting Procedure for Euronext Paris
A sales facility procedure (the “Sales Facility”) will be put in place from 21 June 2024 to 19 July 2024 (the “Sales Facility Period”) to allow shareholders to sell on the NYSE their GE Aerospace shares which are listed on Euronext Paris and held in the Euroclear France clearing system (the “GE Aerospace Euronext Shares”). GE Aerospace has appointed Uptevia to act as centralizing agent under the Sales Facility (the “Centralizing Agent”).
During the Sales Facility Period, shareholders with GE Aerospace Euronext Shares will have the following options:
- sell on a voluntary basis all or part of their GE Aerospace Euronext Shares on the NYSE by participating in the Sales Facility (described in more detail below); or
- retain all or part of their GE Aerospace Euronext Shares, which will continue to be traded on Euronext Paris during the entire Sales Facility Period until and including the trading day prior to the date of the Delisting.
The GE Aerospace Euronext Shares will be delisted from Euronext Paris on 25 July 2024 (the “Delisting Date”).
Shareholders not participating
Shareholders who do not wish to sell their GE Aerospace Euronext Shares under the Sales Facility or directly on Euronext Paris, or have otherwise taken no action by the Delisting Date, will be able to trade their GE Aerospace Euronext Shares on the NYSE, subject to the terms and conditions applied by their financial intermediaries.
Participating shareholders
Shareholders who wish to sell their GE Aerospace Euronext Shares on the NYSE under the Sales Facility should request their financial intermediaries to deliver their GE Aerospace Euronext Shares during the Sales Facility Period to the Centralizing Agent, pursuant to the procedure described below.
The GE Aerospace Euronext Shares delivered to the Centralizing Agent during the Sales Facility Period will be sold on the NYSE as from 26 July 2024 by a broker, at market prices prevailing at the time of the sale. The Centralizing Agent will calculate the average sale price of the GE Aerospace Euronext Shares and will be in charge of transferring the sale proceeds (which will be converted into euros from U.S. dollars by Uptevia) to the GE Aerospace shareholders participating in the Sales Facility once it has received the funds for the sale of all of the GE Aerospace Euronext Shares tendered under the Sales Facility.
GE Aerospace will pay the brokerage commissions on the NYSE for the sale of GE Aerospace Euronext Shares tendered pursuant to the Sales Facility, the fee of the Centralizing Agent and any applicable foreign exchange commission that would be incurred in connection with the Sales Facility.
The Sales Facility procedure is also described in a Euronext notice to be published on 19 June 2024.
No guarantee can be given by GE Aerospace or by the Centralizing Agent as to the price at which the GE Aerospace Euronext Shares tendered pursuant to the Sales Facility will be sold. The Sales Facility is being provided solely as an accommodation to holders of GE Aerospace Euronext Shares. Holders (and in particular individual investors) of GE Aerospace Euronext Shares may decide not to participate in the Sales Facility or may decide not to take any action, in which case no guarantee can be given on the terms, including costs, that would be applied by their financial intermediary after the Delisting. Individual investors are urged to consult their own investment advisors before deciding to participate or not in this process.
The contemplated timetable of the Sales Facility and the Delisting can be summarized as follows (it being specified that GE Aerospace reserves the right to amend this calendar):
Event |
Date |
Sales Facility |
|
Beginning of the Sales Facility |
21 June 2024 |
End of the Sales Facility |
19 July 2024 |
End of the centralization by Uptevia |
23 July 2024 |
Sale on the NYSE of the GE Aerospace Euronext Shares tendered in the Sales Facility |
As from 26 July 2024 |
Settlement of the proceeds of the Sales Facility to the relevant financial intermediary |
As soon as possible after receipt of the proceeds of the Sales Facility |
Delisting |
|
Last day of trading of GE Aerospace Euronext Shares on Euronext Paris |
24 July 2024 |
Delisting of GE Aerospace Euronext Shares on Euronext Paris |
25 July 2024 |
GE Aerospace shareholders participating in the Sales Facility are reminded that they acknowledge and accept (i) the risk implied from the change in the share market price and/or applicable exchange rates between the date on which their shares are delivered to Uptevia for participation in the Sales Facility and the receipt of the applicable average sale proceeds, and (ii) that from the time the GE Aerospace Euronext Shares are delivered to Uptevia, they will not be entitled to any subsequent dividend declared by GE Aerospace. They are also reminded that any orders to tender GE Aerospace Euronext Shares to the Sales Facility are irrevocable, as is the subsequent sale of such GE Aerospace Euronext Shares tendered on the NYSE.
Shareholders may request any additional information from their custodian and usual financial intermediary, who has received the details of the Delisting.
About GE AEROSPACE
GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 44,000 commercial and 26,000 military aircraft engines. With a global team of 52,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow and the future at www.geaerospace.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618573691/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 18:22:00 CEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 17:45:00 CEST | Press release
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global Phase III clinical trial of Omlyclo™ (CT-P39) for the treatment of chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at a satellite symposium during the 2025 European Academy of Dermatology and Venereology (EADV) Congress Celltrion highlights the strength of its expanding dermatology portfolio with positive clinical results for CT-P55, a biosimilar candidate referencing secukinumab With the launch of Omlyclo™, Celltrion underscores its commitment to advancing innovative and accessible treatments in immunology and dermatology Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereo
Andersen Consulting tilføjer samarbejdsfirmaet Charter18.9.2025 17:14:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine digitale transformationskapaciteter gennem en samarbejdsaftale med Charter, et canadisk konsulentfirma, der er specialiseret i IT-strategi, managed services og applikationslevering. Charter blev grundlagt i 1997 og leverer teknologiprojekter med en forretningsorienteret tankegang og dyb teknisk ekspertise, herunder inden for IT-rådgivning, cloud-infrastruktur, cybersikkerhed, applikationsudvikling, projektlevering og forretningsarkitektur. Charter hjælper traditionelle virksomheder, offentlige institutioner, tjenesteudbydere og mellemstore kunder med implementering, netværksinfrastruktur og kundeorienterede applikationer – der leveres gennem en livscyklus-tilgang fra strategi til udførelse. "Vores mål hos Charter har altid været at fjerne kompleksiteten fra IT og hjælpe organisationer med at bevæge sig fremad med tillid," siger Kelly Michell, præsident for Charter. "Vores samarbejde med Andersen Consulting gør det muligt for os at bringe vores integrere
Andersen Consulting udvider sit udbud inden for cybersikkerhed og teknologi med tilføjelsen af Move18.9.2025 17:06:00 CEST | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Move, der er en førende virksomhed inden for it-infrastruktur, driftstjenester og digitale løsninger til virksomheder. Move befinder sig i Norge og Sverige. Move blev grundlagt i 1989 og leverer konsulentydelser, it-løsninger og driftstjenester. Virksomheden har ekspertise inden for cybersikkerhed, cloud-løsninger, server- og lagringsløsninger, netværkskommunikation og implementering af AI. Move samarbejder med mellemstore og store virksomheder om at designe, implementere og drive sikre, skalerbare og fremtidssikrede it-miljøer. "Dette samarbejde er en spændende mulighed for at skabe endnu større værdi for vores kunder," siger Roald Sannæs, der er administrerende direktør i Move. "Med vores kompetencer og Andersen Consultings globale rækkevidde og ekspertise kan vi levere mere helhedsorienterede løsninger, der hjælper organisationer med at løse nutidens udfordringer og forudse fremtidens muligheder." "Move har opbygget et godt ren
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 16:40:00 CEST | Press release
The inaugural ranking by TIME, in partnership with Statista, features AMRA as one of the world’s leading health technology companies that are “driving innovation, enhancing accessibility, and contributing to a more effective and sustainable health care system” AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproduc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom